Temporal inhibition of mouse mammary gland cancer metastasis by CORM-A1 and DETA/NO combination therapy.

Abstract

Carbon monoxide and nitric oxide are two of the most important vasoprotective mediators. Their downregulation observed during vascular dysfunction, which is associated with cancer progression, leads to uncontrolled platelet activation. Therefore, the aim of our studies was to improve vasoprotection and to decrease platelet activation during progression of mouse mammary gland cancer by concurrent use of CO and NO donors (CORM-A1 and DETA/NO, respectively). Methods: Mice injected intravenously with 4T1-luc2-tdTomato or orthotopically with 4T1 mouse mammary gland cancer cells were treated with CORM-A1 and DETA/NO. Ex vivo aggregation and activation of platelets were assessed in the blood of healthy donors and breast cancer patients. Moreover, we analyzed the compounds' direct effect on 4T1 mouse and MDA-MB-231 human breast cancer cells proliferation, adhesion and migration in vitro. Results: We have observed antimetastatic effect of combination therapy, which was only transient in orthotopic model. During early stages of tumor progression concurrent use of CORM-A1 and DETA/NO demonstrated vasoprotective ability (decreased endothelin-1, sICAM and sE-selectin plasma level) and downregulated platelets activation (decreased bound of fibrinogen and vWf to platelets) as well as inhibited EMT process. Combined treatment with CO and NO donors diminished adhesion and migration of breast cancer cells in vitro and inhibited aggregation as well as TGF-β release from breast cancer patients' platelets ex vivo. However, antimetastatic effect was not observed at a later stage of tumor progression which was accompanied by increased platelets activation and endothelial dysfunction related to a decrease of VASP level. Conclusion: The therapy was shown to have antimetastatic action and resulted in normalization of endothelial metabolism, diminution of platelet activation and inhibition of EMT process. The effect was more prominent during early stages of tumor dissemination. Such treatment could be applied to inhibit metastasis during the first stages of this process.

• Authors: Kseniia Porshneva, Diana Papiernik, Mateusz Psurski, Agnieszka Łupicka-Słowik, Rafał Matkowski, Marcin Ekiert, Marcin Nowak, Joanna Jarosz, Joanna Banach, Magdalena Milczarek, Tomasz M Goszczyński, Marcin Sieńczyk, Joanna Wietrzyk
• Journal: Theranostics (Theranostics) Vol. 9 Issue 13 Pg. 3918-3939 ( 2019) ISSN: 1838-7640 [Electronic] Australia
• PMID: 31281522 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Boranes
• Carbonates
• Cell Adhesion Molecules
• Hydrazines
• Microfilament Proteins
• Nitroso Compounds
• PAPA NONOate
• Phosphoproteins
• sodium boranocarbonate
• vasodilator-stimulated phosphoprotein
• 2,2'-(hydroxynitrosohydrazono)bis-ethanamine
• Nitric Oxide

Topics

• Animals
• Antineoplastic Combined Chemotherapy Protocols (pharmacology, therapeutic use)
• Boranes (pharmacology, therapeutic use)
• Carbonates (pharmacology, therapeutic use)
• Cattle
• Cell Adhesion (drug effects)
• Cell Adhesion Molecules (metabolism)
• Cell Line, Tumor
• Cell Movement (drug effects)
• Disease Progression
• Endothelial Cells (drug effects, pathology)
• Endothelium (drug effects, physiopathology)
• Epithelial-Mesenchymal Transition (drug effects)
• Female
• Humans
• Hydrazines (pharmacology)
• Lung Neoplasms (secondary)
• Mammary Neoplasms, Animal (blood supply, drug therapy, pathology)
• Mice, Inbred BALB C
• Microfilament Proteins (metabolism)
• Neoplasm Metastasis
• Nitric Oxide (metabolism, pharmacology)
• Nitroso Compounds (pharmacology, therapeutic use)
• Phosphoproteins (metabolism)
• Phosphorylation (drug effects)
• Platelet Activation (drug effects)
• Time Factors